Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T, Miyamoto T, Fujisaki T, Ohno Y, Kamimura T, Kato K, Takenaka K, Iwasaki H, Eto T, Takamatsu Y, Teshima T, Akashi K; Fukuoka Blood and Marrow Transplant Group (FBMTG). Muta T, et al. Among authors: kamimura t. Intern Med. 2013;52(1):63-70. doi: 10.2169/internalmedicine.52.8390. Epub 2013 Jan 1. Intern Med. 2013. PMID: 23291675 Free article.
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M. Eto T, et al. Among authors: kamimura t. Int J Hematol. 2013 Aug;98(2):186-96. doi: 10.1007/s12185-013-1378-9. Epub 2013 Jun 11. Int J Hematol. 2013. PMID: 23754766
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Miyamoto T, et al. Among authors: kamimura t. Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23. Int J Hematol. 2013. PMID: 23877150 Clinical Trial.
Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study).
Nagafuji K, Miyamoto T, Eto T, Kamimura T, Taniguchi S, Okamura T, Ohtsuka E, Yoshida T, Higuchi M, Yoshimoto G, Fujisaki T, Abe Y, Takamatsu Y, Yokota S, Akashi K, Harada M. Nagafuji K, et al. Among authors: kamimura t. J Hematol Oncol. 2013 Feb 6;6:14. doi: 10.1186/1756-8722-6-14. J Hematol Oncol. 2013. PMID: 23388549 Free PMC article.
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: kamimura t. Cancer Sci. 2009 Oct;100(10):1842-7. doi: 10.1111/j.1349-7006.2009.01268.x. Epub 2009 Jul 1. Cancer Sci. 2009. PMID: 19656156 Free PMC article.
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Seki R, Ohshima K, Nagafuji K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: kamimura t. Int J Hematol. 2010 Mar;91(2):258-66. doi: 10.1007/s12185-009-0475-2. Int J Hematol. 2010. PMID: 20066574
540 results